Stocklytics Platform
Asset logo for symbol ENLV
Enlivex Therapeutics Ltd
ENLV43
$1.14arrow_drop_up8.41%$0.08
Penny Stock
Asset logo for symbol ENLV
ENLV43

$1.14

arrow_drop_up8.41%

Performance History

Chart placeholder
Key Stats
Open$1.15
Prev. Close$1.07
EPS-1.18
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$24.40M
PE Ratio-
LOWHIGH
Day Range1.04
1.20
52 Week Range0.83
4.59
Ratios
Revenue-
EBITDA Margin %-
EPS-1.18

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV) is a biotechnology company focused on developing novel immunotherapies for the treatment of life-threatening diseases. The company's lead product candidate, Allocetra, is a cell therapy designed to modulate the immune system and restore immune balance. Allocetra has shown promising results in preclinical and early clinical trials, demonstrating its potential to treat various indications, including sepsis, solid tumors, and autoimmune diseases.
Enlivex Therapeutics has a strong intellectual property portfolio, with several patents covering the composition, manufacturing, and use of Allocetra. The company's proprietary platform technology enables the production of a consistent and scalable supply of therapeutic cells. This platform has the potential to revolutionize the field of immunotherapy by offering a standardized and reproducible treatment option.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Headquarters
Ness Ziona
Employees
0
Exchange
NASDAQ
add Enlivex Therapeutics Ltd to watchlist

Keep an eye on Enlivex Therapeutics Ltd

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Enlivex Therapeutics Ltd's (ENLV) price per share?

The current price per share for Enlivex Therapeutics Ltd (ENLV) is $1.14. The stock has seen a price change of $0.09 recently, indicating a 8.41% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Enlivex Therapeutics Ltd (ENLV)?

For Enlivex Therapeutics Ltd (ENLV), the 52-week high is $4.59, which is 302.63% from the current price. The 52-week low is $0.83, the current price is 36.53% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Enlivex Therapeutics Ltd (ENLV) a growth stock?

Enlivex Therapeutics Ltd (ENLV) has shown an average price growth of -3.72% over the past three years. It has received a score of 5 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Enlivex Therapeutics Ltd as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Enlivex Therapeutics Ltd (ENLV) stock price performance year to date (YTD)?

As of the latest data, Enlivex Therapeutics Ltd (ENLV) has a year-to-date price change of -65.45%. Over the past month, the stock has experienced a price change of -22.97%. Over the last three months, the change has been -8.8%. Over the past six months, the figure is -17.39%. Looking at a longer horizon, the five-year price change stands at -86.6%.
help

Is Enlivex Therapeutics Ltd (ENLV) a profitable company?

Enlivex Therapeutics Ltd (ENLV) has a net income of -$29.07M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$29.4M. Furthermore, the EBITDA is -$17.89M.
help

What is the market capitalization of Enlivex Therapeutics Ltd (ENLV)?

Enlivex Therapeutics Ltd (ENLV) has a market capitalization of $24.4M. The average daily trading volume is 1.15, indicating the stock's liquidity and investor engagement.

News

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis
ENLIVEX THERAPEUTICS
ALLOCETRA
OSTEOARTHRITIS
PATENT
JAPAN
Oct 30, 2024

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
PRESS RELEASES
COMPANY ANNOUNCEMENT
Jun 17, 2024

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
PRESS RELEASES
COMPANY ANNOUNCEMENT
May 29, 2024

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
PRESS RELEASES
WARRANTS AND CERTIFICATES
CHANGES IN COMPANY'S OWN SHARES
May 28, 2024

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
PRESS RELEASES
COMPANY ANNOUNCEMENT
Apr 16, 2024

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
Apr 15, 2024

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

Take Your Investments to a Whole New Level